In a recently published analysis report, Future Market Insights reveals that the global Cancer Biopsy Market achieved remarkable sales of US$ 22.2 Billion in 2022. Anticipating an impressive 18% Compound Annual Growth Rate (CAGR), the market’s projected growth from 2023 to 2033 is set to surpass historical trends. Notably, the Tissue Biopsies segment is forecasted to emerge as the top revenue generator, with an expected CAGR of nearly 19% during the period spanning from 2023 to 2033.
The increasing elderly populace, along with the rise in instances of cancer diagnoses, is fueling growth in the cancer clinical market. Also, the effective and less costly use of liquid biopsy procedures and increasing biopsy appointees are all expected to impact the market growth.
Claim your complimentary report with captivating visuals.
https://www.futuremarketinsights.com/reports/sample/rep-gb-16508
Some of today’s prominent procedures in medical diagnosis include endoscopic, arthroscopic, bone marrow, skin, needle, and surgical biopsies. Needle biopsies are regarded as a trusted method for the early detection of patients suffering from these methods. However, fine-needle aspiration needle biopsies, which have been found to be less invasive and faster, are aiding the increase in popularity of the slice.
The IARC estimates that by 2020 the worldwide burden of disease due to cancer is projected to be 19.3 million cases and 9.96 million deaths worldwide. A liquid biopsy entails reduced expense, earlier prognosis, therapy surveillance, identification of tumor heterogeneity, acquired drug resistance, and patient comfort compared to conventional diagnostic tools for handling cancer.
Competitive Analysis
Key companies are helping to drive market expansion by diversifying their diagnostics portfolios and increasing the adoption of their own biopsy tools.
Key recent developments of key players in the Cancer Biopsy Market are as follows:
- In March 2021, in Russia, KIllumina, Inc. received medical device approval for their NextSeq 550Dx platform and related reagent kits. Prior to this registration, the MiSeq Dx had already been approved as a medical device.
- In March 2021, Autopsy with Quick-Core IZI Medical Products introduced a system for soft tissue biopsy procedures. This fully automated product is based on Quick-Core, the company’s patented semi-automatic method.
Click Here to Request Methodology!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16508
Competitive Landscape
Key companies are helping to drive market expansion by diversifying their diagnostics portfolios and increasing the adoption of their own biopsy tools.
- In March 2021, In Russia, KIllumina, Inc. has received medical device approval for their NextSeq 550Dx platform and related reagent kits. Prior to this registration, the MiSeq Dx had already been approved as a medical device.
- In March 2021, Autopsy with a Quick-Core IZI Medical Products has introduced a system for soft tissue biopsy procedures. This fully automated product is based on Quick-Core, the company’s patented semi-automatic method.
- In April 2021, Sysmex Europe GmbH and Sysmex Inostics GmbH introduced Plasma-SeqSensei liquid biopsy research use only (RUO) kits in EMEA.
More Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the Cancer Biopsy Market, presenting historical market data (2018-2022) and forecast statistics for the period of 2023-2033.
The study reveals essential insights on the basis of by Type (Tissue Biopsies, Liquid biopsies, Other Types), by Product Type (Instruments, Kits and Consumables, Services), by Application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Liver Cancers, Pancreatic Cancers, Ovarian Cancers, Other Applications) across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).
Market Segments Covered in Cancer Biopsy Industry Analysis
By Type:
- Tissue Biopsies
- Needle Biopsies
- Surgical Biopsies
- Liquid Biopsies
- Other Types
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/16508
By Product Type:
- Instruments
- Kits and Consumables
- Services
By Application:
- Breast Cancer
- Colorectal Cancer
- Cervical Cancers
- Lung Cancers
- Prostate Cancers
- Skin Cancers
- Blood Cancers
- Kidney Cancers
- Liver Cancers
- Pancreatic Cancers
- Ovarian Cancers
- Other Applications
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube